[1]Yogeswaran K， Fung SK. Chronic hepatitis B in pregnancy: unique challenges and opportunities. Korean J Hepatol，2011，17（1）:1-8.
[2] Pawlotsky JM，Dusheiko G，Hatzakis A，et a1. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice:recommendations for a standardized approach. Gastroenterology，2008，134（2）:405-415.
[3] Pallier C，Rodriguez C，Brillet R，et a1.Complex dynamics of hepatitis B virus resistance to adefovir. Hepatology，2009，49（1）:50-59.
[4] Yamahan T，Sertioz R，Pullukcu H，et a1. A case of chronic hepatitis B with primary adefovir resistance. Mikrobiyol Bul，2007，41（2）:297-301．
[5] Schildgen O，Sirma H，Funk A，et a1. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med，2006， 354（17）:l807-l8l2.
[6] Yeon JE，Yoo W，Hong SP，et a1. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil.Gut，2006，55（10）:1488-1495.
[7] Fung SK，Chae HB，Fontana RJ，et a1. Virologic response and resistance to adefovir in patients with chronic hepatitis B. Hepatology，2006，44（2）:283-290.
[8] 邵幼林，陈良云，吴金华. LAM耐药后ADV序贯治疗再耐药HBV变异株的动态变化.世界华人消化杂志，2010，18（18）：1895-1901.
[9] Cui XJ，Cho YK，Song HI，et a1. Molecular characteristics and functional analysis of full-length hepatitis B virus quasispecies from a Patient with chronic hepatitis B virus infection. Virus Res，2010，150（1-2）:43-48.
[10] 蒋自卫，史文高. 乙型肝炎病毒基因变异和耐药与临床肝病的关系. 临床肝胆病杂志，2010，26（4）：438-440，445.
[11] Takkenberg RB，Zaaijer HL，Molenkamp R，et a1. Validation of a sensitive and specific real-time PCR for detection and quantitation of hepatitis B virus covalently closed circular DNA in plasma of chronic hepatitis B patients. J Med Virol，2009，81（6）:988-995.
[12] Kock J，Baumert TF，Delaney WE，et a1. Inhibitory effect of adfovir and lamivudine on the initiation of hepatitis B virus infection in primary tupaia hepatocytes. Hepatology，2003，38（6）:1410-1418.
[13] Yadav V，Chu CK. Molecular mechanisms of adefovir sensitivity and resistance in HBV polymerase mutants:a molecular dynamics study. Bioorg Med Chem Lett，2004，14（16）:4313-4317.
[14] 徐东平. 乙型肝炎病毒耐药的检测方法与临床意义. 解放军医学杂志，2010，35（6）：611-613.
[15] Lok AS，Zoulim F，Locarnini S，et a1. Antiviral drug resistant HBV:standardization of nomenclature and assays and recommendations for management. Hepatology，2007，46（1）:254-265.
[16] Degertekin B，Hussain M，Tan J，et al. Sensitivity and accuracy of an updated line probe assay（HBV DR v.3） in detecting mutations associated with hepatitis B antiviral resistance. Hepatology，2009，50（1）:42-48.
[17] Ayoub WS，Keeffe eb. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther，2008，28（2）:167-177.
[18] 吴超飞，秦劲锋，周彬，等. 阿德福韦酯单药及其联合拉米夫定治疗拉米夫定耐药型HBeAg阳性慢性乙型肝炎的疗效比较. 热带医学杂志，2010，10（4）：423-425.
[19] Lampertico P，Vigano M，Manenti E，et a1. Low resistance to adefovir combined with lamivudine:a 3-year study of 145 lamivudine resistant hepatitis B patients.Gastroenterology，2007，133（12）:1445-1451.
[20] 周淑云，张亚杰.阿德福韦酯对拉米夫定耐药的慢性乙型肝炎患者的疗效观察. 临床肝胆病杂志，2010，26（2）：178-179，186.
[21] Delaney WE，Ray AS，Yang H，et a1. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus.Antimi Agents Chemother，2006，50（7）:2471-2477.
[22] Laoi BN，Herra C，Norris S，et al. First report of genotypic resistance to adefovir in chronic HBV in the Republic of Ireland. J Antimicrob Chemother，2006，57（5）:l009-10l0.
[23] Schildgen O，Sirma H，Funk A，et a1. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med. 2006，354（17）:l807-l8l2.
[24] Yuen MF，Lai CL. Treatment of chronic hepatitis B: Evolution over two decades. Gastroenterol Hepatol，2011，26（Suppl 1）:138-143.
[25] 罗先平，经继生，陈红波，等. 干扰素联合阿德福韦酯治疗慢性乙型肝炎2年随访. 肝脏，2010，15（3）：233-234.
[26] 胡莹，马福宝. 乙型肝炎病毒感染者免疫治疗的研究进展. 江苏预防医学，2010，21（3）：68-70. |
